A medication of major therapeutic importance for patients, which must remain accessible and manufactured in France. 🏭
With a €2.5 million investment and a complete industrial transfer to France, we are choosing to strengthen health sovereignty and to control the entire value chain in order to guarantee patients safe, sustainable and responsible access to treatment. 🎯
The first boxes produced in France for French patients are expected in 2026.
✅ The consolidation of global Meteospasmyl production, supported by an investment of over €15 million at our historic site in Dammarie-lès-Lys, in the Île-de-France region, with the creation of 40 qualified industrial jobs by 2026. The first boxes were released last month, for France and worldwide — over €50 million in exported production.
✅ Over the next two years, €30 million will be invested in production, innovation, decarbonization and relocation projects in France.

No comments yet, be the first to comment.